{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', \"Bartalena L. Graves' orbitopathy: imperfect treatments for a rare disease. European thyroid\", 'journal. 2013; 2(4): 259-69.', 'Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on', \"Graves' orbitopathy (EUGOGO) on management of GO. European journal of endocrinology.\", '2008; 158(3): 273-85.', 'Bartalena L, Krassas GE, Wiersinga W, et al. Efficacy and safety of three different cumulative', \"doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.\", 'The Journal of clinical endocrinology and metabolism. 2012; 97(12): 4454-63.', \"Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and\", 'perspectives. Endocrine reviews. 2000; 21(2): 168-99.', 'Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated', 'with autoimmune thyroid disease in Olmsted County, Minnesota. Transactions of the American', 'Ophthalmological Society. 1994; 92: 477-588.', 'Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow-up of Graves ophthalmopathy in', 'an incidence cohort. Ophthalmology. 1996; 103(6): 958-62.', 'Boschi A, Daumerie C, Spiritus M, et al. Quantification of cells expressing the thyrotropin', 'receptor in extraocular muscles in thyroid associated orbitopathy. The British journal of', 'ophthalmology. 2005; 89(6): 724-9.', \"Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and\", 'management. Endocrine reviews. 1993; 14(6): 747-93.', \"Coulter I, Frewin S, Krassas GE, et al. Psychological implications of Graves' orbitopathy.\", 'European journal of endocrinology. 2007; 157(2): 127-31.', 'Dickinson AJ. (2010). Clinical manifestations. In W. M. Wiersinga & G. J. Kahaly (Eds.),', \"Graves' orbitopathy: a multidisciplinary approach - questions and answers (2nd ed.): Karger\", 'Basel.', 'Dolman PJ, Cahill K, Czyz CN, et al. Reliability of estimating ductions in thyroid eye disease: an', 'International Thyroid Eye Disease Society multicenter study. Ophthalmology. 2012; 119(2):', '382-9.', 'Douglas RS, Gianoukakis AG, Kamat S, et al. Aberrant expression of the insulin-like growth', \"factor-1 receptor by T cells from patients with Graves' disease may carry functional\", 'consequences for disease pathogenesis. Journal of immunology (Baltimore, Md : 1950). 2007;', '178(5): 3281-7.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 111 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', \"Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves' disease aberrantly\", 'express the IGF-1 receptor: implications for disease pathogenesis. Journal of immunology', '(Baltimore, Md : 1950). 2008; 181(8): 5768-74.', 'Ezra DG, Rose GE, Bailly M. Genome Level Microarray Expression Profiling Implicates IGF-1', 'And Wnt Signalling Dysregulation In The Pathogenesis Of Thyroid Associated Ophthalmopathy.', 'Investigative Ophthalmology & Visual Science. 2011; 52(14): 5100-.', 'Gasinska T, Borowska A, Wichary H, et al. Effect of methylprednisolone pulse therapy with and', \"without alendronate on biochemical markers of bone turnover in patients with Graves'\", 'ophthalmopathy. Polskie Archiwum Medycyny Wewnetrznej. 2012; 122(7-8): 341-7. -', \"Gerding MN, Terwee CB, Dekker FW, et al. Quality of life in patients with Graves'\", 'ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument.', 'Thyroid : official journal of the American Thyroid Association. 1997; 7(6): 885-9.', 'Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-', \"controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001;\", '108(9): 1523-34.', \"Investigator's Brochure. Investigator's brochure for teprotumumab (HZN-001) human anti-IGF-1\", 'receptor antibody for ophthalmic indications including thyoid eye disease: 7th edition, 07 July', '2017. Horizon Pharma USA.', \"Kahaly GJ. (2010). Management of moderately severe Graves' orbitopathy. In W. M. Wiersinga\", \"& G. J. Kahaly (Eds.), Graves' orbitopathy: a multidisciplinary approach - questions and\", 'answers (2nd ed.): Karger Basel.', \"Kahaly GJ, Petrak F, Hardt J, et al. Psychosocial morbidity of Graves' orbitopathy. Clinical\", 'endocrinology. 2005; 63(4): 395-402.', 'Mallika P, Tan A, Aziz S, et al. Thyroid associated ophthalmopathy - a review. Malaysian family', 'physician : the official journal of the Academy of Family Physicians of Malaysia. 2009; 4(1): 8-', '14.', 'Melamud B, Lurie Y, Goldin E, et al. Methylprednisolone-induced liver injury: a diagnostic', 'challenge. The Israel Medical Association journal : IMAJ. 2014; 16(3): 180-1.', 'Mostbeck A, Galvan G, Bauer P, et al. The incidence of hyperthyroidism in Austria from 1987 to', '1995 before and after an increase in salt iodization in 1990. European journal of nuclear', 'medicine. 1998; 25(4): 367-74.', 'Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease', \"activity in Graves' ophthalmopathy: a novel approach. The British journal of ophthalmology.\", '1989; 73(8): 639-44.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 112 of 117']\n\n###\n\n", "completion": "END"}